Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ACAD's Cash to Debt is ranked higher than
90% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. ACAD: No Debt )
ACAD' s 10-Year Cash to Debt Range
Min: 5.56   Max: 98090
Current: No Debt

5.56
98090
Equity to Asset 0.97
ACAD's Equity to Asset is ranked higher than
99% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ACAD: 0.97 )
ACAD' s 10-Year Equity to Asset Range
Min: -2.13   Max: 0.98
Current: 0.97

-2.13
0.98
Interest Coverage No Debt
ACAD's Interest Coverage is ranked higher than
85% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACAD: No Debt )
ACAD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 160.03
M-Score: -9.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -69853.64
ACAD's Operating margin (%) is ranked lower than
52% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. ACAD: -69853.64 )
ACAD' s 10-Year Operating margin (%) Range
Min: -4212.45   Max: 35.82
Current: -69853.64

-4212.45
35.82
Net-margin (%) -69234.55
ACAD's Net-margin (%) is ranked lower than
52% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. ACAD: -69234.55 )
ACAD' s 10-Year Net-margin (%) Range
Min: -4040.5   Max: 35.93
Current: -69234.55

-4040.5
35.93
ROE (%) -27.03
ACAD's ROE (%) is ranked higher than
76% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. ACAD: -27.03 )
ACAD' s 10-Year ROE (%) Range
Min: -138.68   Max: 72.43
Current: -27.03

-138.68
72.43
ROA (%) -26.03
ACAD's ROA (%) is ranked higher than
74% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. ACAD: -26.03 )
ACAD' s 10-Year ROA (%) Range
Min: -78.95   Max: 34.38
Current: -26.03

-78.95
34.38
ROC (Joel Greenblatt) (%) -14597.07
ACAD's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. ACAD: -14597.07 )
ACAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21643.52   Max: 2028.76
Current: -14597.07

-21643.52
2028.76
Revenue Growth (%) -79.10
ACAD's Revenue Growth (%) is ranked higher than
57% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ACAD: -79.10 )
ACAD' s 10-Year Revenue Growth (%) Range
Min: -79.1   Max: 73.1
Current: -79.1

-79.1
73.1
» ACAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ACAD Guru Trades in Q4 2013

Andreas Halvorsen 2,630,645 sh (New)
Steven Cohen 171,060 sh (+8.39%)
» More
Q1 2014

ACAD Guru Trades in Q1 2014

Ron Baron 492,442 sh (New)
Steven Cohen 1,153,694 sh (+574.44%)
Andreas Halvorsen 3,598,407 sh (+36.79%)
» More
Q2 2014

ACAD Guru Trades in Q2 2014

Andreas Halvorsen 4,757,878 sh (+32.22%)
Steven Cohen 1,082,000 sh (unchged)
Ron Baron 437,000 sh (-11.26%)
» More
Q3 2014

ACAD Guru Trades in Q3 2014

Paul Tudor Jones 10,748 sh (New)
Ron Baron 502,100 sh (+14.9%)
Andreas Halvorsen 4,324,890 sh (-9.1%)
Steven Cohen 925,000 sh (-14.51%)
» More
» Details

Insider Trades

Latest Guru Trades with ACAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Andreas Halvorsen 2014-06-30 Add 32.22%0.11%$17.82 - $25.095 $ 30.0244%4757878
Andreas Halvorsen 2014-03-31 Add 36.79%0.1%$21.87 - $30.1 $ 30.0219%3598407
Ron Baron 2014-03-31 New Buy0.05%$21.87 - $30.1 $ 30.0219%492442
Andreas Halvorsen 2013-12-31 New Buy0.31%$19.86 - $28.84 $ 30.0228%2630645
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.50
ACAD's P/B is ranked higher than
65% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. ACAD: 9.50 )
ACAD' s 10-Year P/B Range
Min: 0.48   Max: 16.77
Current: 9.5

0.48
16.77
EV-to-EBIT -35.10
ACAD's EV-to-EBIT is ranked higher than
77% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACAD: -35.10 )
ACAD' s 10-Year EV-to-EBIT Range
Min: -72.2   Max: 6.3
Current: -35.1

-72.2
6.3
Current Ratio 30.31
ACAD's Current Ratio is ranked higher than
97% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. ACAD: 30.31 )
ACAD' s 10-Year Current Ratio Range
Min: 2.27   Max: 46.41
Current: 30.31

2.27
46.41
Quick Ratio 30.31
ACAD's Quick Ratio is ranked higher than
97% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ACAD: 30.31 )
ACAD' s 10-Year Quick Ratio Range
Min: 2.27   Max: 46.41
Current: 30.31

2.27
46.41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.60
ACAD's Price/Net Cash is ranked higher than
82% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. ACAD: 9.60 )
ACAD' s 10-Year Price/Net Cash Range
Min: 0.69   Max: 19.49
Current: 9.6

0.69
19.49
Price/Net Current Asset Value 9.60
ACAD's Price/Net Current Asset Value is ranked higher than
81% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. ACAD: 9.60 )
ACAD' s 10-Year Price/Net Current Asset Value Range
Min: 0.69   Max: 109
Current: 9.6

0.69
109
Price/Tangible Book 9.50
ACAD's Price/Tangible Book is ranked higher than
71% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. ACAD: 9.50 )
ACAD' s 10-Year Price/Tangible Book Range
Min: 0.63   Max: 13.63
Current: 9.5

0.63
13.63
Price/DCF (Projected) 25.00
ACAD's Price/DCF (Projected) is ranked higher than
91% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACAD: 25.00 )
ACAD' s 10-Year Price/DCF (Projected) Range
Min: 15.58   Max: 19.65
Current: 25

15.58
19.65
Earnings Yield (Greenblatt) -2.80
ACAD's Earnings Yield (Greenblatt) is ranked higher than
80% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ACAD: -2.80 )
ACAD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.8   Max: 51153
Current: -2.8

-2.8
51153

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DR6.Germany,
ACADIA Pharmaceuticals Inc was incorporated in Vermont in 1993 as Receptor Technologies, Inc. The Company reincorporated in Delaware in 1997. It is a biopharmaceutical Company engaged in the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Pimavanserin is a new chemical entity that the Company discovered and has advanced to Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Parkinsons disease psychosis is a debilitating disorder that develops in up to 60 percent of patients with Parkinsons disease. The Company has completed a Phase II trial with pimavanserin as a co-therapy in schizophrenia and has established plans for a future Phase II feasibility study to explore the use of pimavanserin as a treatment for Alzheimers disease psychosis. In collaboration with Allergan, it has discovered and is developing small molecule product candidates for the treatment of chronic pain. Chronic pain is a common form of persistent pain that may be related to a number of medical conditions and is often resistant to treatment. Allergan has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome. The Company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. This program has reached Phase I development. ACADIA and R-SAT are company's registered trademarks. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. It is subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.
» More Articles for ACAD

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
comment on ACAD Mar 02 2013 
ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 05 2009 
ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009 Jul 29 2009 
ACADIA Pharmaceuticals Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor... Dec 08 2014
ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor... Dec 08 2014
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences Nov 25 2014
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences Nov 25 2014
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 19 2014
ACADIA PHARMACEUTICALS INC Financials Nov 19 2014
ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20,... Nov 13 2014
ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20,... Nov 13 2014
ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20,... Nov 13 2014
10-Q for ACADIA Pharmaceuticals, Inc. Nov 12 2014
Acadia misses 3Q profit forecasts Nov 10 2014
Acadia misses 3Q profit forecasts Nov 10 2014
ACADIA Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today Nov 10 2014
ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of... Nov 10 2014
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 10 2014
ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of... Nov 10 2014
Q3 2014 ACADIA Pharmaceuticals Inc Earnings Release - After Market Close Nov 10 2014
ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014 Nov 03 2014
ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014 Nov 03 2014
Jim Cramer's Top Stock Picks: TWTR TASR ACAD ISIS RH Sep 12 2014
Biotech targets: Cramer's quality candidates Sep 11 2014
[video] Cramer: ACAD and ISIS have room to run Sep 11 2014
Why ACADIA Pharmaceuticals (ACAD) Stock Is Spiking Today Sep 02 2014
Compuware Climbs On Buyout Announcement Sep 02 2014
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Sep 02 2014
ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin)... Sep 02 2014
ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin Aug 28 2014
ACAD: Acadia On Track With Pimavanserin Development Program Aug 06 2014
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 05 2014
ACADIA Pharmaceuticals Prices Public Offering of Common Stock Mar 07 2014
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences Mar 05 2014
ACADIA Pharmaceuticals Prices Public Offering of Common Stock Mar 04 2014
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock Mar 03 2014
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31,... Feb 27 2014
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February... Feb 20 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK